🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Myeloid Malignancy

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission NCT05909293NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Venclexta 100 MG Oral Tablet Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia NCT06956755n/a1 site📍 Rouen Groupe Francophone des Myelodysplasies Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX NCT06782971n/a4 sites📍 Canberra📍 Sydney📍 Sydney Clinical Hub for Interventional Research (CHOIR) Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients NCT07303660Phase 16 sites📍 Moscow📍 Krasnogorsk📍 Velikiy Novgorod Lomond Therapeutics Holdings, Inc. · Tests: ZE50-0134, Azacitidine Days 1-7, ZE 50-0134 Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT00801489Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin HVA vs IA/DA or VA in the Treatment of ND HR-AML NCT06810791Phase 31 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: HVA, VA, Standard Chemotherapy Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations NCT07032727Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib, Cladribine (CLAD), Venetoclax, Gilteritinib, Ruxolitinib A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas NCT07003542Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Sitagliptin A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites📍 Birmingham📍 Leeds📍 London Imperial College London · Tests: EBX-102, Placebo Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder NCT07844694Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Sirolimus Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia NCT04793919Phase 231 sites📍 Brussels📍 Prague📍 Aarhus N Associazione Italiana Ematologia Oncologia Pediatrica · Tests: Mylotarg, Arsenic Trioxide, All-trans retinoic acid Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML NCT05807932Phase 1, Phase 26 sites📍 Aachen📍 Düsseldorf📍 Cologne Heinrich-Heine University, Duesseldorf · Tests: Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia NCT04659616Phase 12 sites📍 Portland📍 Dallas OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies NCT06668584Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant NCT06543381Phase 12 sites📍 Duarte📍 Cleveland City of Hope Medical Center · Tests: Biospecimen Collection, Olutasidenib IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) NCT06647862Phase 343 sites📍 Hefei📍 Beijing📍 Chongqing ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Tests: IMM01, Azacitidine, Placebo Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773n/a1 site📍 Hong Kong The University of Hong Kong A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib NCT06284486Phase 1, Phase 24 sites📍 Baltimore📍 Boston📍 New York M.D. Anderson Cancer Center · Tests: Venetoclax, Revumenib A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) NCT06782373Phase 239 sites📍 Scottsdale📍 Boston📍 Rochester Swedish Orphan Biovitrum · Tests: Pacritinib, Placebo Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. NCT06483906Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Venetoclax, Azacitidine and Homoharringtonine Ziftomenib Maintenance Post Allo-HCT NCT06440135Phase 12 sites📍 Boston📍 Columbus Massachusetts General Hospital · Tests: Ziftomenib Assessment of Geriatric Evaluations Impact on New AML Guidance NCT05909501n/a1 site📍 Philadelphia Abramson Cancer Center at Penn Medicine Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) NCT05580601Phase 1, Phase 21 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati · Tests: CIML-NK Cells A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy